GoAI
Get started
NewAmsterdam Pharma Company N.V. logo

NewAmsterdam Pharma Company N.V.

NAMS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$27.87

+$0.09 · +0.32%

Aug 21, 4:00 PM ET

NAMS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

32

Expensive

Momentum

45

Neutral

Sentiment

70

Bullish

Risk resilience

64

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Headquarters
NL
CEO
Michael Davidson
Listed since
Feb 9, 2021
Employees
100

Market position

Day range

Current $27.87

52-week range

Current $27.87

Open
$27.99
Previous close
$27.78
Volume
525.43K
0.43× average
Average volume
1.22M
Average daily volume
Market cap
3.26B USD
Beta
0.11
Market reference 1
50-day average
$30.579
-8.86% below average
200-day average
$33.1481
-15.92% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.52B USD
P/E (TTM)
-12.78×
P/B (TTM)
5.45×
P/S (TTM)
457.54×
EV / EBITDA
-14.54×
Earnings yield
-5.08%
Free cash flow yield
-3.69%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
92.15%
Operating margin
-3432.20%
Net margin
-3644.21%
Return on equity
-29.82%
Return on assets
-26.49%
Return on invested capital
-33.01%

Financial health

Debt / equity
0×
Current ratio
7.88×
Altman Z-score
24.84
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends240%-320%-879%-1438%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 99.74%Operating margin, FY2022: -3.46%Operating margin, FY2023: -1298.56%Operating margin, FY2024: -386.91%Operating margin, FY2025: -1002.90%Net margin, FY2022: -22.04%Net margin, FY2023: -1255.76%Net margin, FY2024: -530.25%Net margin, FY2025: -905.74%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 99.74%. Operating margin FY2022 -3.46%. Operating margin FY2023 -1298.56%. Operating margin FY2024 -386.91%. Operating margin FY2025 -1002.90%. Net margin FY2022 -22.04%. Net margin FY2023 -1255.76%. Net margin FY2024 -530.25%. Net margin FY2025 -905.74%.

Income trends

Revenue

22.5M USD-50.61%

Operating income

−225.68M USD-28.02%

Net income

−203.82M USD+15.64%
Income trends across reported periods137.12M USD−593.6K USD−138.31M USD−276.03M USDRevenue, FY2022: 102.69M USDRevenue, FY2023: 14.09M USDRevenue, FY2024: 45.56M USDRevenue, FY2025: 22.5M USDOperating income, FY2021: −34.98M USDOperating income, FY2022: −3.56M USDOperating income, FY2023: −182.97M USDOperating income, FY2024: −176.29M USDOperating income, FY2025: −225.68M USDNet income, FY2021: −41.79M USDNet income, FY2022: −22.63M USDNet income, FY2023: −176.94M USDNet income, FY2024: −241.6M USDNet income, FY2025: −203.82M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 102.69M USD. Revenue FY2023 14.09M USD. Revenue FY2024 45.56M USD. Revenue FY2025 22.5M USD. Operating income FY2021 −34.98M USD. Operating income FY2022 −3.56M USD. Operating income FY2023 −182.97M USD. Operating income FY2024 −176.29M USD. Operating income FY2025 −225.68M USD. Net income FY2021 −41.79M USD. Net income FY2022 −22.63M USD. Net income FY2023 −176.94M USD. Net income FY2024 −241.6M USD. Net income FY2025 −203.82M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue22.5M USD45.56M USD14.09M USD102.69M USD—
Cost of goods sold59K USD————
Gross profit22.44M USD45.56M USD14.09M USD102.69M USD—
Research and development141.83M USD151.41M USD159.42M USD86.74M USD28.97M USD
Selling, general, and administrative106.3M USD70.45M USD37.63M USD19.51M USD5.68M USD
Operating expenses248.13M USD221.85M USD197.06M USD106.25M USD34.98M USD
Interest income27.59M USD16.88M USD10.22M USD——
Interest expense——6.8M USD287K USD411K USD
Depreciation and amortization220K USD113K USD49K USD9K USD5K USD
Operating income−225.68M USD−176.29M USD−182.97M USD−3.56M USD−34.98M USD
Net income−203.82M USD−241.6M USD−176.94M USD−22.63M USD−41.79M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$51.33

84.18% upside
Past 12 months12-month forecastHigh $58.00Average $51.33Low $45.00

Rating distribution

10 ratings
Strong buy00%
Buy990%
Hold110%
Sell00%
Strong sell00%

NAMS news

defenseworld.net

NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lessened its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 70.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The…

Read source
seekingalpha.com

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

Read source
marketbeat.com

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of…

Read source
zacks.com

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48.

Read source
globenewswire.com

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS…

Read source
globenewswire.com

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral,…

Read source

NAMS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NAMS

Funds reporting this stock among their holdings, ordered by reported position size.

Capital Group U.S. Small and Mid Cap ETF logoCapital Group U.S. Small and Mid Cap ETFCGMM
Market value
19.4M
Weight
0.57%
AUM
3.4B USD
Expense ratio
0.51%
Price / 1D
$33.09+0.67%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
16.69M
Weight
0.16%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
5.09M
Weight
0.02%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
ALPS Medical Breakthroughs ETF logoALPS Medical Breakthroughs ETFSBIO
Market value
3.82M
Weight
1.62%
AUM
236.37M USD
Expense ratio
0.50%
Price / 1D
$69.11+0.80%
Fidelity Fundamental Small-Mid Cap ETF logoFidelity Fundamental Small-Mid Cap ETFFFSM
Market value
1.44M
Weight
0.11%
AUM
1.5B USD
Expense ratio
0.43%
Price / 1D
$37.31+0.84%
iShares ESG Aware MSCI USA Small-Cap ETF logoiShares ESG Aware MSCI USA Small-Cap ETFESML
Market value
1.11M
Weight
0.04%
AUM
2.92B USD
Expense ratio
0.17%
Price / 1D
$55.83+0.65%
Fidelity Nasdaq Composite Index ETF logoFidelity Nasdaq Composite Index ETFONEQ
Market value
962.63K
Weight
0.01%
AUM
10.35B USD
Expense ratio
0.21%
Price / 1D
$103.14+0.41%
Fidelity MSCI Health Care Index ETF logoFidelity MSCI Health Care Index ETFFHLC
Market value
802.4K
Weight
0.02%
AUM
3.29B USD
Expense ratio
0.08%
Price / 1D
$84.66+1.22%

Continue in GoAI

Research NAMS

research.disclaimer